Healing & Recovery

TB-500 (synthetic fragment of Thymosin Beta-4)

Synthetic 17-amino-acid fragment representing the actin-binding active region of Thymosin Beta-4.

EmergingBy ModernPeptideScience Editorial · Updated April 2026

At a glance

What it is: Synthetic 17-amino-acid fragment representing the actin-binding active region of Thymosin Beta-4..

Primary research applications:

Tissue repair and regeneration research
Soft-tissue and tendon recovery
Cardiovascular and wound-healing models

Editorial summary: TB-500 is best understood in relation to its parent molecule, full-length Thymosin Beta-4 (TB-4), which has a substantial human clinical research program in cardiac repair, dry-eye disease, and wound healing. TB-500 as a separate, shorter synthetic compound has a smaller direct human evidence base — much of its credibility in user communities rests on extrapolation from TB-4 work plus growing interest in its actin-binding properties.

Class / structure: Synthetic 17-amino-acid fragment (Ac-LKKTETQ-region of TB-4)
Half-life: Short systemic half-life; sustained tissue interactions
First described: TB-4 isolated 1981; TB-500 marketed in research-peptide space subsequently
Regulatory status: Not FDA-approved; FDA Category 2 (503A bulks list) since 2023

What is TB-500?

TB-500 is a synthetic 17-amino-acid fragment sold as the 'active region' of Thymosin Beta-4 (TB-4), a 43-amino-acid naturally occurring actin-sequestering peptide found in virtually all human cells. Importantly, TB-500 and full-length TB-4 are not the same molecule: TB-4 has an extensive research program including human trials, while TB-500 as marketed is a separate, shorter compound.^[1]

TB-500 is not FDA-approved. Like BPC-157, it was placed on the FDA's 503A Category 2 bulks list in late 2023, restricting compounding pharmacies from producing it.

Mechanism of action

Full-length Thymosin Beta-4 is the major actin-sequestering protein in mammalian cells, involved in cell motility, angiogenesis, and tissue repair. Proposed mechanisms relevant to healing include:

Upregulation of actin and promotion of cell migration to injury sites
Angiogenesis (new blood vessel formation)
Recruitment of stem/progenitor cells to damaged tissues
Modulation of inflammation

TB-500 is claimed to retain the key actin-binding region of TB-4 (sequence LKKTETQ and the surrounding residues). Whether the fragment truly reproduces the full molecule's activity in humans is itself an open question.

What the research shows

The peer-reviewed literature on TB-500 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

Claims and the evidence behind them

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Claim	What the evidence shows	Verdict
Heals tendons, ligaments, and muscle injuries in humans	Rodent data; no human RCTs	Preliminary
Reduces inflammation systemically	Preclinical anti-inflammatory signal; no human RCT	Preliminary
Reaches injury sites preferentially	Claim based on TB-4's known cell migration mechanism; not tested in humans	Uncertain
Is equivalent to full-length Thymosin Beta-4 for therapeutic purposes	TB-500 is a shorter fragment; equivalence not established	Unsupported
Is banned by WADA	Yes, TB-4 and analogs including TB-500 are prohibited	Supported

Reported user experiences

The reports below are aggregated from research forums, podcasts, and self-experimenters. They are useful as hypothesis-generating signals — patterns worth investigating in controlled studies — but they are not controlled data. Selection effects, placebo response, and underreporting of side effects all apply.

Commonly reported benefits

Faster recovery from soft tissue injuries (most common report)
Reports of reduced joint pain
Subjectively 'systemic' effects — healing at distant injury sites
Commonly stacked with BPC-157; users often can't distinguish individual contributions

Commonly reported side effects

Mostly reported as well-tolerated short-term
Fatigue or 'flu-like' symptoms after doses in some reports
Concerns about angiogenic activity and theoretical tumor-promotion — no documented human cases but limited data

How the research describes administration

In preclinical research and animal use, subcutaneous and intramuscular injection are the common routes. There is no validated human clinical protocol.

This site does not provide usage guidance.

Editorial note

Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.

Safety considerations and open questions

The takeaway

TB-500 inherits some of the credibility of Thymosin Beta-4's preclinical and early clinical story, but the marketed fragment has not been validated in its own right in humans. It's best understood as a plausible peptide with a supportive rodent literature and essentially no rigorous human efficacy data — similar to BPC-157, with which it's almost always paired. The common online stacking with BPC-157 reflects anecdotal practice, not clinical evidence.

Frequently asked questions

Is TB-500 the same as Thymosin Beta-4?

No. Thymosin Beta-4 is the full 43-amino-acid naturally occurring peptide, with an established research program and some human clinical data (mainly ophthalmology and cardiac repair). TB-500 is a 17-amino-acid synthetic fragment claimed to represent TB-4's active region. They are related but not interchangeable in the published evidence base.

Does TB-500 heal injuries in humans?

There are no published human randomized controlled trials demonstrating this. Preclinical data in rodents and anecdotal user reports are the current basis for the claim.

Is TB-500 legal?

It is not approved for human therapeutic use in the US or other major markets. It is banned by WADA for athletes. Following the 2023 FDA action, it is excluded from the 503A compounding pathway.

Why is TB-500 almost always paired with BPC-157?

The pairing is an online convention, not a clinical protocol. Users claim the combination provides systemic (TB-500) plus localized (BPC-157) healing. This is not supported by published combination studies in humans.

Is TB-500 dangerous?

Short-term tolerability reports are generally good. Long-term human safety data is absent. The angiogenic and cell-proliferative mechanism raises theoretical long-term concerns that have not been investigated.

Does TB-500 cause cancer?

No evidence that it does. But also no systematic human cancer-risk data. The pro-angiogenic mechanism is worth ongoing attention.

How is TB-500 administered?

In research settings: subcutaneous or intramuscular injection. This is descriptive, not a usage guide.

Is TB-500 effective for racehorses?

It is widely used in equine medicine, particularly for soft tissue injuries. Equine use does not establish human safety or efficacy. Multiple major racing jurisdictions have banned it from competition.

References

Crockford D, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-89. https://pubmed.ncbi.nlm.nih.gov/20592997/
Sosne G, Kleinman HK. Primary mechanisms of thymosin β4 repair activity in dry eye disorders and other tissue injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110-7. https://pubmed.ncbi.nlm.nih.gov/26241398/
Dubé KN, Smart N. Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease. Expert Opin Biol Ther. 2018;18(sup1):131-139. https://pubmed.ncbi.nlm.nih.gov/30063870/
U.S. FDA 503A Category 2 listing for Thymosin Beta-4 and related fragments. 2023. https://www.fda.gov/drugs/human-drug-compounding/503a-bulk-drug-substances-nominations-use-compounding